In this clinic-focused program, review current and emerging strategies for personalizing AML treatment with expert-authored commentaries, and an on-demand Webcast capturing expert discussion from the 2018 hematologic malignancies symposium in San Diego. Then download the meeting slidesets and decision support resources on prognostic factors and key AML clinical trials to help guide your AML treatment recommendations.
New targeted agents are improving outcomes in newly diagnosed and relapsed/refractory AML. How can we optimize our diagnostic and treatment approaches for patients based on karyotype, FLT3 status, and other biomarkers?
New drugs and drug combinations, particularly targeted therapies, are changing the treatment paradigm for patients with newly diagnosed and relapsed/refractory AML.
At ASH 2018, exciting new data were presented on targeted therapy–based regimens for patients with newly diagnosed AML or unfit for conventional chemotherapy along with data on novel immunotherapies.
Watch this on-demand Webcast from the CCO AML satellite symposium at ASH 2018, featuring expert faculty Stéphane de Botton, MD, PhD, Mark J. Levis, MD, PhD, Farhad Ravandi, MD, Gary J. Schiller, MD, and Eunice S. Wang, MD, as they present the latest clinical advances in treatment strategies for patients with AML, including newly approved agents.
Download and use this handy reference guide to review currently recruiting phase III clinical trials in acute myeloid leukemia for your patients with AML.
Download and use this handy reference to help guide the use of prognostic factors in treatment decisions for your patients with acute myeloid leukemia (AML).
Download this slideset from a live ASH symposium reviewing the current and future management of acute myeloid leukemia (AML) using antibody-based therapies including antibody-drug conjugates.
Download this slideset from a live ASH symposium reviewing the challenges and treatment options, including recently approved agents, for patients with newly diagnosed acute myeloid leukemia (AML).
Download this slideset from a live ASH symposium reviewing the latest treatment approaches, including newly approved agents, for patients with FLT3-mutated AML.
Download this slideset from a live ASH symposium reviewing the latest treatment approaches, including newly approved agents, for patients with IDH-mutated AML.
Download this slideset from a live ASH symposium reviewing newly approved and investigational agents for AML.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.